SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial
Posted 29 Jul 2020
Dr Kevin Fernando summarises results from the cardiovascular outcomes trial of ertugliflozin presented at the American Diabetes Association’s 2020 congress, along with the implications for primary care.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.